Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check2 days agoChange DetectedThe page now displays Revision: v3.5.3, replacing Revision: v3.5.2. This indicates a minor update to the page's build/version metadata rather than a change to visible content.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded Cabozantinib Versus Sunitinib as Initial Targeted Therapy publication (CABOSUN trial) citation in Publications and removed the prior CABOSUN entry (revision v3.5.0).SummaryDifference0.1%

- Check23 days agoChange DetectedPadua, Italy, 35128 was replaced with Padova, Italy, 35128 in the locations section.SummaryDifference0.0%

- Check37 days agoChange DetectedThe Napoli, Italy, 80131 site listing was changed to Naples, Italy, 80131. The city name now uses the English form.SummaryDifference0.0%

- Check45 days agoChange DetectedDifference0.2%

- Check52 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.